FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to monoclonal antibodies to activated protein C (aPC). Amino acid sequences of the heavy chain and light chain of the monoclonal antibody are shown in SEQ ID NO: 5–26, and CDR sequences are shown in SEQ ID NO: 27–92. Present invention further provides a biological material bound to a monoclonal antibody and a monoclonal antibody capable of selectively binding to aPC and not to non-activated protein C, as well as the use of the monoclonal antibody and the associated biological material in the preparation of a medicinal agent for treating disorders associated with a deficiency or defect of coagulation, and a related method of treatment.
EFFECT: antibodies according to the present invention can block anticoagulant activity of aPC and have wide application potential in treating disorders associated with deficiency or defect of coagulation.
20 cl, 7 dwg, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| THERAPEUTIC BIOPREPARATION FOR TREATING HEPATOCELLULAR CARCINOMA | 2014 |
|
RU2739218C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
